Pancreatic Enzyme Replacement Therapy: Wales

The Department has worked in close partnership with the devolved administrations in the management of this supply issue. The Department is continuing to engage with all suppliers of pancreatic enzyme replacement therapy (PERT) to mitigate the supply issue that is affecting the whole of the United Kingdom. Through this work, we have managed to secure additional volumes of PERT for 2025 for the UK. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market.

In December 2024, the Department issued further management advice to healthcare professionals, which was then discussed with and cascaded to all the devolved administrations. This directs clinicians to consider these unlicensed imports when licensed stock is unavailable, and includes actions for integrated care boards to ensure local mitigation plans are put in place and implemented. The Department, in collaboration with NHS England, has created a webpage to include the latest updates on PERT availability and easily accessible advice on the prescribing and ordering of alternative PERT products.

The Department has frequent conversations with representatives from the impacted patient groups, so that they are informed of the supply situation and the mitigation actions being taken.

The Department will also continue to meet with suppliers, patient groups, and other relevant stakeholders across the supply chain to provide updates on the supply position and the actions being taken to address them.